The interaction between tumor cells and the tumor microenvironment (TME) plays an important role in tumor development and drug resistance. Thus, there is a need for appropriate tumor models resembling the situation in vivo enabling the development of new treatment approaches and making therapy decisions. We address these issues mainly by two approaches:
- Precision-cut tumor slices maintaining the three-dimensional architecture and tumor heterogeneity can be used to study the TME and evaluate the drug treatment efficacy.
- Patient derived organoid based on tumor cells can be supplemented with other compartments of the TME such as fibroblasts and immune cells and are a reproducible test system for the evaluation of experimental therapies.